Anna M. Wu

University of California, Irvine — United States

Medicine · Health Sciences

68h-index22.1kcitations370works1.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(154), Radiopharmaceutical Chemistry and Applications(127), CAR-T cell therapy research(48), Prostate Cancer Treatment and Research(40), Immunotherapy and Immune Responses(34)

Publications369 total

NLRP10 engages oxidized DNA through a Schiff-base mechanism and dissociates from NLRP3 upon inflammasome activation
Communications Biology·2026Open Access
89Zr-anti-CD8 immunoPET visualizes heterogeneous intratumoral CD8+ immune responses to treatment with radiation and anti-CTLA4
npj Imaging·2025Open Access
First-in-human phase I trial combining radiopharmaceutical therapy (RPT) using a 90y-anti-CD25 monoclonal antibody (Mab) with total marrow and lymphoid irradiation (TMLI) in relapsed or refractory (R/R) acute leukemia
Blood·2025
309 Combining radiopharmaceutical therapy with CAR T cells to overcome the heterogeneous immunosuppressive prostate tumor microenvironment
Regular and Young Investigator Award Abstracts·2025Open Access
957 Modulation of the tumor immune microenvironment by low dose antibody-based radiopharmaceutical therapy (RPT) and direct visualization of RPT analog microdistribution by imaging mass cytometry
Regular and Young Investigator Award Abstracts·2025Open Access
Reengineered Anti-CD4 Cys-diabody Variants for 89Zr-immunoPET of CD4+ T Cells in Immunocompetent Mice
Molecular Imaging and Biology·2025Open Access
Radiation-resistant Ti/BN coatings: insights from 171 days exposure to space radiation and atomic oxygen in low orbit
npj Materials Degradation·2025· 3 citedOpen Access
89Zr-anti-CD8 immunoPET visualizes heterogeneous intratumoral CD8+ immune responses to treatment with radiation and anti-CTLA4 in a preclinical syngeneic breast cancer model
2025Open Access
NLRP10 Cleaves Oxidized DNA inhibited by OGG1 inhibitors: A Newly Identified Role in DNA Damage Processing and Senescence Regulation
2025· 1 citedOpen Access
Cu-64-Anti-CEA M5A as a Novel Theranostics PET Imaging Agent Pre and Post Neoadjuvant Radiotherapy in Advanced Rectal Cancer
International Journal of Radiation Oncology*Biology*Physics·2024
First-in-man study of the PSMA Minibody IR800-IAB2M for molecularly targeted intraoperative fluorescence guidance during radical prostatectomy
European Journal of Nuclear Medicine and Molecular Imaging·2024· 17 citedOpen Access
Yttrium-90 anti-CD25 BEAM conditioning for autologous hematopoietic cell transplantation in Peripheral T-cell lymphoma
Blood Advances·2024· 1 citedOpen Access
Figure S7 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
2024Open Access
Figure S3 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
2024Open Access
Supplemental Tables from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
2024Open Access
Figure S6 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
2024Open Access
Figure S5 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
2024Open Access
Figure S6 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
2024Open Access
Data from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
2024Open Access
Data from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
2024Open Access
page 1 of 19Next →

Frequent Co-authors

Andrew Raubitschek(15), Lawrence E. Williams(14), John E. Shively(13), Paul J. Yazaki(11), Tove Olafsen(11), Sanjiv S. Gambhir(10), Felix B. Salazar(6), Jeffrey Y.C. Wong(6), Gobalakrishnan Sundaresan(5), Richard Tavaré(5), Vania Kenanova(4), David Iklé(4), Stephen J. Forman(4), Melissa McCracken(3), Kirstin A. Zettlitz(3), Owen N. Witte(3), Neeta Pandit‐Taskar(3), David Colcher(3), Robert E. Reiter(3), David Z. J. Chu(3)